Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YM155 in Unresectable or Metastatic Melanoma
NCT00281541Phase 2Completed
- Sponsor
- Astellas Pharma
- Start
- Nov 2005
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sepantronium in melanoma, sponsored by Astellas Pharma. Started Nov 2005; status: completed.
02
Drugs
sepantronium
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00281541.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00281541.